MedTrace Logo

A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

NCT02656043 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2019-01-22

No results posted yet for this study

Summary

Phase 1/2 study enrolling up to 60 healthy volunteers in Phase 1 followed by approximately 150 subjects with acne vulgaris in Phase 2.

Conditions

  • Acne Vulgaris

Interventions

DRUG

XPF-005

Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Xenon Pharmaceuticals Inc. · Xenon Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-17
Primary Completion
2017-02-16
Completion
2017-03-17

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656043 on ClinicalTrials.gov